The effectiveness of early colchicine administration in patients over 60 years old with high risk of developing severe pulmonary complications associated with coronavirus pneumonia SARS-CoV-2 (COVID-19) : study protocol for an investigator-driven randomized controlled clinical trial in primary health care-COLCHICOVID study
© 2021. The Author(s)..
BACKGROUND: There is no strong evidence that any drug is beneficial either for the treatment of SARS-CoV-2 disease or for post-exposure prophylaxis. Therefore, clinical research is crucial to generate results and evaluate strategies against COVID-19. Primary care (PC) centers, the first level of care in the health system, are in a favorable position to carry out clinical trials (CD), as they work with a large volume of patients with varied profiles (from acute to chronic pathologies). During the COVID-19 pandemic, the need for hospital admission and mortality is higher in people > 60 years. Therefore, this is a target population to try to reduce the serious complications and lethality of COVID pneumonia and to avoid overloading the hospital system. Given the pharmacological properties of colchicine (anti-inflammatory and anti-fibrotic, possible inhibition of viral replication, and inhibitory effect on coagulation activation), early treatment with colchicine may reduce the rate of death and serious pulmonary complications from COVID-19 in vulnerable patients.
METHODS: The COLCHICOVID study is a randomized, multicenter, controlled, open-label parallel group (2:1 ratio), phase III clinical trial to investigate the efficacy of early administration of colchicine in reducing the development of severe pulmonary complications associated with COVID-19 infection in patients over 60 years of age with at-risk comorbidities.
DISCUSSION: This is a pragmatic clinical trial, adapted to usual clinical practice. The demonstration that early administration of colchicine has clinical effectiveness in reducing the complications of SARS-CoV-2 infection in a population highly susceptible may mitigate the health crisis and prevent the collapse of the health system in the successive waves of the coronavirus pandemic. In addition, colchicine is a well-known medicine, simple to use in the primary care setting and with a low cost for the health system.
TRIAL REGISTRATION: ClinicalTrials.gov NCT04416334 . Registered on 4 June 2020. Protocol version: v 3.0, dated 22 September 2020.
Medienart: |
E-Artikel |
---|
Erscheinungsjahr: |
2021 |
---|---|
Erschienen: |
2021 |
Enthalten in: |
Zur Gesamtaufnahme - volume:22 |
---|---|
Enthalten in: |
Trials - 22(2021), 1 vom: 06. Sept., Seite 590 |
Sprache: |
Englisch |
---|
Beteiligte Personen: |
Estebanez, Elena Bustamante [VerfasserIn] |
---|
Links: |
---|
Themen: |
Clinical Trial Protocol |
---|
Anmerkungen: |
Date Completed 08.09.2021 Date Revised 03.04.2024 published: Electronic ClinicalTrials.gov: NCT04416334 Citation Status MEDLINE |
---|
doi: |
10.1186/s13063-021-05544-7 |
---|
funding: |
|
---|---|
Förderinstitution / Projekttitel: |
|
PPN (Katalog-ID): |
NLM330312456 |
---|
LEADER | 01000caa a22002652 4500 | ||
---|---|---|---|
001 | NLM330312456 | ||
003 | DE-627 | ||
005 | 20240403233339.0 | ||
007 | cr uuu---uuuuu | ||
008 | 231225s2021 xx |||||o 00| ||eng c | ||
024 | 7 | |a 10.1186/s13063-021-05544-7 |2 doi | |
028 | 5 | 2 | |a pubmed24n1362.xml |
035 | |a (DE-627)NLM330312456 | ||
035 | |a (NLM)34488841 | ||
040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
041 | |a eng | ||
100 | 1 | |a Estebanez, Elena Bustamante |e verfasserin |4 aut | |
245 | 1 | 4 | |a The effectiveness of early colchicine administration in patients over 60 years old with high risk of developing severe pulmonary complications associated with coronavirus pneumonia SARS-CoV-2 (COVID-19) |b study protocol for an investigator-driven randomized controlled clinical trial in primary health care-COLCHICOVID study |
264 | 1 | |c 2021 | |
336 | |a Text |b txt |2 rdacontent | ||
337 | |a ƒaComputermedien |b c |2 rdamedia | ||
338 | |a ƒa Online-Ressource |b cr |2 rdacarrier | ||
500 | |a Date Completed 08.09.2021 | ||
500 | |a Date Revised 03.04.2024 | ||
500 | |a published: Electronic | ||
500 | |a ClinicalTrials.gov: NCT04416334 | ||
500 | |a Citation Status MEDLINE | ||
520 | |a © 2021. The Author(s). | ||
520 | |a BACKGROUND: There is no strong evidence that any drug is beneficial either for the treatment of SARS-CoV-2 disease or for post-exposure prophylaxis. Therefore, clinical research is crucial to generate results and evaluate strategies against COVID-19. Primary care (PC) centers, the first level of care in the health system, are in a favorable position to carry out clinical trials (CD), as they work with a large volume of patients with varied profiles (from acute to chronic pathologies). During the COVID-19 pandemic, the need for hospital admission and mortality is higher in people > 60 years. Therefore, this is a target population to try to reduce the serious complications and lethality of COVID pneumonia and to avoid overloading the hospital system. Given the pharmacological properties of colchicine (anti-inflammatory and anti-fibrotic, possible inhibition of viral replication, and inhibitory effect on coagulation activation), early treatment with colchicine may reduce the rate of death and serious pulmonary complications from COVID-19 in vulnerable patients | ||
520 | |a METHODS: The COLCHICOVID study is a randomized, multicenter, controlled, open-label parallel group (2:1 ratio), phase III clinical trial to investigate the efficacy of early administration of colchicine in reducing the development of severe pulmonary complications associated with COVID-19 infection in patients over 60 years of age with at-risk comorbidities | ||
520 | |a DISCUSSION: This is a pragmatic clinical trial, adapted to usual clinical practice. The demonstration that early administration of colchicine has clinical effectiveness in reducing the complications of SARS-CoV-2 infection in a population highly susceptible may mitigate the health crisis and prevent the collapse of the health system in the successive waves of the coronavirus pandemic. In addition, colchicine is a well-known medicine, simple to use in the primary care setting and with a low cost for the health system | ||
520 | |a TRIAL REGISTRATION: ClinicalTrials.gov NCT04416334 . Registered on 4 June 2020. Protocol version: v 3.0, dated 22 September 2020 | ||
650 | 4 | |a Clinical Trial Protocol | |
650 | 4 | |a Journal Article | |
650 | 4 | |a Colchicine | |
650 | 4 | |a Coronavirus | |
650 | 4 | |a Early treatment | |
650 | 4 | |a No hospitalized | |
650 | 4 | |a Primary health care | |
650 | 7 | |a Colchicine |2 NLM | |
650 | 7 | |a SML2Y3J35T |2 NLM | |
700 | 1 | |a Alconero, Lucía Lavín |e verfasserin |4 aut | |
700 | 1 | |a Fernández, Beatriz Josa |e verfasserin |4 aut | |
700 | 1 | |a Marguello, Monica Gozalo |e verfasserin |4 aut | |
700 | 1 | |a Caro, Juan Carlos López |e verfasserin |4 aut | |
700 | 1 | |a Vallejo, Jonathan Diez |e verfasserin |4 aut | |
700 | 1 | |a Sampedro, Marta Fernandez |e verfasserin |4 aut | |
700 | 1 | |a Cacho, Pedro Muñoz |e verfasserin |4 aut | |
700 | 1 | |a Espiga, Carlos Richard |e verfasserin |4 aut | |
700 | 1 | |a Saiz, María Mar García |e verfasserin |4 aut | |
773 | 0 | 8 | |i Enthalten in |t Trials |d 2006 |g 22(2021), 1 vom: 06. Sept., Seite 590 |w (DE-627)NLM161320430 |x 1745-6215 |7 nnns |
773 | 1 | 8 | |g volume:22 |g year:2021 |g number:1 |g day:06 |g month:09 |g pages:590 |
856 | 4 | 0 | |u http://dx.doi.org/10.1186/s13063-021-05544-7 |3 Volltext |
912 | |a GBV_USEFLAG_A | ||
912 | |a GBV_NLM | ||
951 | |a AR | ||
952 | |d 22 |j 2021 |e 1 |b 06 |c 09 |h 590 |